Discovery of 5,6-Bis(4-methoxy-3-methylphenyl)pyridin-2-amine as a WSB1 Degrader to Inhibit Cancer Cell Metastasis.
Jinxin CheZegao JinFangjie YanJieqiong YouJiangfeng XieBinhui ChenGang ChengHong ZhuQiaojun HeYongzhou HuBo YangJi CaoXiao-Wu DongPublished in: Journal of medicinal chemistry (2021)
The gain of cell motility is an essential prerequisite for cancer metastasis. The ubiquitin ligase subunit WD repeat and SOCS box-containing 1 (WSB1) has been demonstrated to regulate hypoxia-driven tumor cell migration. However, there is still a lack of methods for discovering inhibitors targeting the WSB1 axis. Here, we employed phenotypic screening models and identified compound 4 that displayed migration inhibitory activity against WSB1-overexpressing cells. Further studies indicated that it may function as a WSB1 degrader, thus leading to the accumulation of the Rho guanosine diphosphate dissociation inhibitor 2 (RhoGDI2) protein, reversing the expression of downstream F-actin and formation of membrane ruffles, and disturbing the migration capacity of cancer cells. Moreover, compound 4 exhibited a promising in vivo anticancer metastatic effects. Our findings show the discovery of a new WSB1 degrader, providing a unique solution for the treatment of cancer metastasis.
Keyphrases
- cell migration
- papillary thyroid
- small molecule
- squamous cell
- binding protein
- poor prognosis
- small cell lung cancer
- induced apoptosis
- single cell
- high throughput
- stem cells
- protein kinase
- ionic liquid
- endothelial cells
- lymph node metastasis
- transcription factor
- cell therapy
- cancer therapy
- staphylococcus aureus
- long non coding rna
- drug delivery
- candida albicans